Moderna reaffirms that its vaccine is 94.1% effective in primary analysis
– Vaccine was 94.1% effective in analysis of Phase 3 study, after 196 virus cases
– Vaccine was 100% effective against severe virus cases in trial
– Vaccine was 94.1% effective in analysis of Phase 3 study, after 196 virus cases
– Vaccine was 100% effective against severe virus cases in trial